Yes, I did. I think the Privacy Commissioner was obviously also asked to comment on this bill under short notice. So we did explain to the Privacy Commissioner that we are interested in the pathogens and how they're handled and contained. We're not interested in personal information to do with the patients that the samples have come from, for instance.
They were also interested in, say, if the SARS virus escaped from a lab, infected a lab worker, and then infected the family members, whether we would then know personal information about family members, etc. I think from our perspective we're interested only in what happened in the lab that resulted in an infection and how we could actually do that better, as opposed to the public health domain, which will take care of the patients who are ill and the family members. So there is no need for us to have that kind of personal information.
They were also interested in our security clearance and what we are proposing. We are not proposing anything different from security clearance practices and how we hold information along the lines of other government departments that demand security clearance for other purposes.
They were satisfied with that explanation, and we reiterated that we will be doing privacy impact assessment on the program during the regulation development and as we are moving into that with them, and they were very satisfied with that.